Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4493
Structure:
Synonyms:
1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione
2,4-IMIDAZOLIDINEDIONE,
2,4-IMIDAZOLIDINEDIONE, 5,5-DIMETHYL-3-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)-
5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione
5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione
5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin
5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
5-24-05-00358 (Beilstein Handbook Reference)
63612-50-0
AB00053180
Anandron
Aventis Behring Brand of Nilutamide
Aventis Brand of Nilutamide
BPBio1_000920
BRN 0841906
BSPBio_000836
BSPBio_003325
C021277
C08164
C12H10F3N3O4
CAS-63612-50-0
CHEBI:7573
D00965
DB00665
DivK1c_006998
EU-0100879
Hoechst Brand of Nilutamide
KBio1_001942
KBio2_002105
KBio2_004673
KBio2_007241
KBio3_002545
KBioGR_001100
KBioSS_002105
Lopac-N-8534
Lopac0_000879
LS-79181
MLS002154066
N8534_SIGMA
NCGC00015754-01
NCGC00015754-02
NCGC00025280-01
NCGC00025280-02
NCGC00025280-03
NCGC00025280-04
NCGC00025280-05
NCGC00025280-06
NCGC00025280-07
NCGC00025280-08
Nilandron
Nilandron (TN)
Nilandrone
Nilutamida
Nilutamida [Spanish]
Nilutamide
Nilutamide (USAN/INN)
Nilutamide [USAN:BAN:INN]
Nilutamide [USAN:INN:BAN]
Nilutamidum
Nilutamidum [Latin]
Prestwick0_000928
Prestwick1_000928
Prestwick2_000928
Prestwick3_000928
RU 23908
RU 23908-10
RU-23908
SMR001233381
SPBio_002125
SPBio_003015
SpecPlus_000902
SPECTRUM1504152
Spectrum2_001973
Spectrum3_001633
Spectrum4_000600
Spectrum5_001512
Spectrum_001625
ST075550
Tocris-1759
ZINC03874498
ATC-Codes:
Side-Effects:
Side-EffectFrequency
flushes0.26000002
urinary tract infection0.0844
nausea0.08279999
constipation0.0582
dyspnea0.0555
dizziness0.047000006
abnormal vision0.047000002
hypertension0.0422
weight increase0.0010
interstitial pneumonitis0.0010
urticaria0.0010
cold extremities0.0010
vomiting0.0010
palpitation0.0010
hepatitis0.0010
angina pectoris0.0010
anxiety0.0010
aplastic anemia0.0010
rash0.0010
gynecomastia0.0010
headache0.0010
hirsutism0
pain0
gastrointestinal hemorrhage0
peripheral edema0
diarrhea0
asthenia0
dyspepsia0
insomnia0
increased sweating0
rhinitis0
nocturia0
cataract0
decreased libido0
anemia0
photophobia0
melena0
somnolence0
arthritis0
leukopenia0
lung disorder0
upper respiratory tract infection0
syncope0
testicular atrophy0
alopecia0
anorexia0
malaise0
dry mouth0
cough0
heart failure0
blurred vision0
fever0
hematuria0
sgot increased0
pruritus0
paresthesia0
pneumonia0
back pain0
edema0
dry skin0
influenza0
chest pain0
abdominal pain0
bone pain0
sweating0
impotence0
tachycardia0
cerebrovascular accident0
interstitial lung disease0
hyperglycemia0
alkaline phosphatase increased0
nervousness0
weight loss0

Target

show target details
Uniprot ID:CP2CJ_HUMAN
Synonyms:
(R)-limonene 6-monooxygenase
(S)-limonene 6-monooxygenase
(S)-limonene 7-monooxygenase
CYPIIC17
CYPIIC19
Cytochrome P450 2C19
Mephenytoin 4-hydroxylase
P450-11A
P450-254C
EC-Numbers:1.14.13.48
1.14.13.49
1.14.13.80
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

1785203
Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes.. Y Horsmans; D Lannes; D Larrey; M Tinel; P Letteron; J Loeper; D Pessayre (1991) Xenobiotica; the fate of foreign compounds in biological systems display abstract
1. The effects of nilutamide (an anti-androgen with a hydantoin moiety) on the 4-hydroxylation of mephenytoin were studied in rat liver microsomes. Nilutamide, at a concentration expected in human liver (100 microM) during prolonged administration of nilutamide, inhibited by 40% mephenytoin (0.3 mM) 4-hydroxylase activity in liver microsomes from untreated male rats, but not in microsomes from untreated female rats, or in microsomes from dexamethasone-treated male or female rats. 2. Administration to male rats of nilutamide, in doses (20 mg/kg i.p. twice daily) known to reproduce plasma concentrations observed in human therapeutics, decreased by 60% the 24 h urinary excretion of 4-hydroxymephenytoin after administration of mephenytoin (15 mg/kg oral). 3. Nilutamide (100 microM) markedly inhibited mephenytoin 4-hydroxylase activity in human liver microsomes. Inhibition kinetics were consistent with mixed inhibition. It is concluded that nilutamide inhibits mephenytoin 4-hydroxylase activity in untreated male rats and in human liver microsomes. It is suggested that inhibition is likely to occur in vivo in humans receiving therapeutic doses of nilutamide.